Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;130(10):599-604.
doi: 10.1111/apm.13265. Epub 2022 Aug 15.

Cytohistological findings in HPV-negative cases from HPV primary screening programme: quality assurance study

Saara Kares  1 , Ivana Kholová  1   2 , Mika Tirkkonen  1 , Risto Vuento  3 , Paula Kujala  1
Affiliations

Cytohistological findings in HPV-negative cases from HPV primary screening programme: quality assurance study

Saara Kares et al. APMIS. 2022 Oct.

Abstract

To evaluate the risk of false HPV-negative results and possible related morphological abnormalities in HPV primary cervical cancer screening. Out of 53,661 HPV-negative cases, 5469 (10.2%) randomly selected cytology slides were evaluated as a part of the quality assurance protocol. The Bethesda category negative for intraepithelial lesion or malignancy (NILM) in the HPV-negative cases given was present in 95.4%. Due to cytology other than NILM, 0.4% of cases were referred to colposcopy and 4.2% to the follow-up in one year. In the follow-up HPV negativity and NILM cytology was present in 88.3% of attended women. Cases other than HPV negative and NILM were referred to colposcopy. One biopsy-proven histological HSIL was found in the first round and one in follow-up screening. More comprehensive genotyping of HSIL cases revealed genotypes 69 and 11. Only two HPV test negative cases with histological HSIL were revealed forming 0.04% of quality control group. In both cases, HPV genotype not included in screening tests was found. According to the results, the primary HPV test with cytology triage is an efficient and specific method for cervical cancer screening despite of the fact that some non-high-risk genotypes are missed.

Keywords: Cervical cancer screening; HPV-negative cancer; Pap smear; cervical cytology; human papilloma virus infection.

PubMed Disclaimer

References

    1. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32. https://doi.org/10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3. Erratum in: Lancet. 2015 Oct 10;386(10002):1446.
    1. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007 Jan;104(1):232-46. https://doi.org/10.1016/j.ygyno.2006.08.053. Epub 2006 Nov 3.
    1. Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579-83. https://doi.org/10.1016/j.cmi.2019.09.006. Epub 2019 Sep 17.
    1. Cervical Cancer Screening Current Guidelines, Working Group set by the Finnish Medical Society Duodecim and The Finnish Colposcopic Society 2019. [(accessed on 3 February 2022)]. Available online: www.kaypahoito.fi
    1. Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research. Available online: https://cancerregistry.fi/screening/cervical-cancer-screening/